Opsona Therapeutics is a leading clinical stage biopharmaceutical company focused on the treatment of autoimmune/inflammatory diseases and cancers.
We are innovators in the field of innate immunity research and are actively identifying new ways to prevent and treat these diseases.
Our drug discovery and development is focused on the role of Toll-Like Receptors (TLRs) and Inflammasome signalling in human immunology. Since 2004, Opsona has also developed a unique and advanced pipeline of drugs at our research locations in Dublin, Ireland. Find out more about Opsona
Opsona Therapeutics Ltd. initiates a prospective open label Phase I/II study in second-line lower (Low and intermediate-1) risk myelodysplastic syndrome (MDS) with OPN-305, a First-in Class Monoclonal
Through innovation and cutting edge research we have developed OPN-305, an antibody to reduce pro-inflammatory cytokine production, which is now at the clinical testing phase.
Our research is focused on the concept that Toll Like Receptors are mediators of inflammation and are key to understanding and developing treatments for the immune system.